Investigators in this project will continue to benefit from a state of the art facility, with advanced nstrumentation and highly trained technicians at their disposal. The personnel have unique experience in sorting extremely rare cells to high purity and in obtaining nine color data with small sample sizes. They routinely handle human specimens with biohazard precautions, and can work with spores, live bacteria and bacterial products. There is no equivalent expertise in the State of Oklahoma. Costs are contained in part by OMRF institutional support. Training is another important activity of this core facility. While investigators can simply hand samples to the technicians and receive formatted data, they are encouraged to learn at least how to analyze their own results. Most students and postdoctoral fellows prefer this, and a few have even earned how to sort on the FACSAria with close supervision. Advice on related procedures, such as reagent selection and magnetic bead enrichments is also readily available. Many appropriately labeled antibodies are available to facilitate pilot experiments and encourage innovation.

Public Health Relevance

Progress on many of these projects hinges on the ability to identify and characterize immune effector cells during Anthrax infection. That includes determination of cell surface markers, intracellular cytokines and signaling molecules. Cell populations required for further analysis can be sorted to extremely high purity.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19AI062629-09
Application #
8379027
Study Section
Special Emphasis Panel (ZAI1-KS-I)
Project Start
Project End
Budget Start
2012-09-01
Budget End
2013-08-31
Support Year
9
Fiscal Year
2012
Total Cost
$56,564
Indirect Cost
$9,493
Name
Oklahoma Medical Research Foundation
Department
Type
DUNS #
077333797
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104
Dumas, Eric K; Garman, Lori; Cuthbertson, Hannah et al. (2017) Lethal factor antibodies contribute to lethal toxin neutralization in recipients of anthrax vaccine precipitated. Vaccine 35:3416-3422
Keshari, Ravi S; Silasi, Robert; Lupu, Cristina et al. (2017) In vivo-generated thrombin and plasmin do not activate the complement system in baboons. Blood 130:2678-2681
Marsman, Gerben; von Richthofen, Helen; Bulder, Ingrid et al. (2017) DNA and factor VII-activating protease protect against the cytotoxicity of histones. Blood Adv 1:2491-2502
Remesh, Soumya G; Andreatta, Massimo; Ying, Ge et al. (2017) Unconventional Peptide Presentation by Major Histocompatibility Complex (MHC) Class I Allele HLA-A*02:01: BREAKING CONFINEMENT. J Biol Chem 292:5262-5270
Healy, Laura D; Puy, Cristina; Fernández, José A et al. (2017) Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in vivo. J Biol Chem 292:8616-8629
Dumas, Eric K; Gross, Timothy; Larabee, Jason et al. (2017) Anthrax Vaccine Precipitated Induces Edema Toxin-Neutralizing, Edema Factor-Specific Antibodies in Human Recipients. Clin Vaccine Immunol 24:
Wang, Xiaoqiu; Wu, Wenxin; Zhang, Wei et al. (2017) RIG-I overexpression decreases mortality of cigarette smoke exposed mice during influenza A virus infection. Respir Res 18:166
Keshari, Ravi Shankar; Silasi, Robert; Popescu, Narcis Ioan et al. (2017) Inhibition of complement C5 protects against organ failure and reduces mortality in a baboon model of Escherichia coli sepsis. Proc Natl Acad Sci U S A :
Patel, Vineet I; Booth, J Leland; Duggan, Elizabeth S et al. (2017) Transcriptional Classification and Functional Characterization of Human Airway Macrophage and Dendritic Cell Subsets. J Immunol 198:1183-1201
Patel, Vineet Indrajit; Metcalf, Jordan Patrick (2016) Identification and characterization of human dendritic cell subsets in the steady state: a review of our current knowledge. J Investig Med 64:833-47

Showing the most recent 10 out of 109 publications